Pulmatrix (PULM)
NASDAQ:PULM
Want to see PULM full AI Analyst Report?
PULM Stock Chart & Stats
$2.35
-$0.25(-3.99%)
At close: 4:00 PM EST
$2.35
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.16 - $9.15
Previous CloseN/A
Volume31.27K
Average Volume (3M)7.19K
Market Cap
$5.33M
Enterprise Value$2.15M
Total Cash (Recent Filing)$3.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-153.89
Enterprise Value/Ebitda-0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Strategic Merger And Platform AcquisitionThe planned all-stock merger brings a new AI-driven MitoXcel peptide platform and leadership, materially changing the company’s strategic direction. This creates a durable operational pivot into gerotherapeutics with dedicated capital and management to advance clinical milestones over coming quarters.
Incremental Working Capital From Preferred FinancingThe $1M preferred placement provides immediate runway and signals affiliate support tied to the merger. While modest, this durable injection reduces near-term funding pressure and helps maintain operations and merger process momentum while larger financing and integration take effect.
Low Leverage — No DebtAbsence of debt limits fixed financing costs and preserves balance-sheet flexibility, important for a clinical-stage biotech. With no scheduled interest or principal obligations, management can prioritize clinical investment or equity financing decisions without near-term creditor constraints.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow forces continuous reliance on external financing, eroding shareholder value over time. Persistent burn constrains the ability to self-fund trials or commercialization activities and increases dilution or financing-execution risk across the next several quarters.
No Sustainable Revenue And Ongoing LossesWith no recurring revenue and negative margins, the business remains dependent on financing rather than operations. That structural absence of commercial cash flow limits long-term sustainability, makes model viability contingent on R&D success, and heightens sensitivity to capital markets conditions.
Severely Eroded Equity And Asset BaseMaterial shrinkage of assets and shareholders’ equity reduces financial cushioning and heightens vulnerability to adverse events. Reduced asset base limits collateral and increases the probability of dilutive financing; it weakens the company's ability to absorb setbacks during costly clinical development.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.16 and its highest was $9.15 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $5.33M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on May 15, 2026. The company reported -$0.321 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.321.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.321 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.84% Mutual Funds
0.56% Other Institutional Investors
96.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---